12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $172M | -$285M | 0.0% | -158.4% | -441.6% | -53.9% | -$323M | — | $135M |
| 2024 | $24M | -$319M | 0.0% | -1434.4% | -110.6% | -44.0% | -$275M | — | $154M |
| 2023 | $0 | -$209M | — | — | -37.8% | -34.2% | -$161M | — | $295M |
| 2022 | $0 | -$149M | — | — | -31.9% | -30.0% | -$134M | — | $74M |
| 2021 | $140M | $25M | 0.0% | 18.8% | 6.1% | 5.5% | $29M | — | $222M |
| 2020 | $2M | -$73M | 0.0% | -4708.2% | -29.0% | -24.3% | -$71M | — | $115M |
| 2019 | $2M | -$56M | 0.0% | -3792.9% | -177.4% | -88.2% | — | — | $25M |
| 2018 | $2M | -$74M | 0.0% | -5001.7% | -139.4% | -88.1% | -$69M | — | $34M |
| 2017 | $2M | -$61M | 0.0% | -2939.0% | -58.3% | -44.3% | -$47M | — | $35M |
| 2016 | $1M | -$44M | 0.0% | -3587.4% | -52.9% | -40.8% | -$35M | — | $24M |
| 2015 | — | -$24M | — | — | 9.6% | -26.8% | — | — | $23M |
| 2014 | — | -$20M | — | — | 13.0% | — | — | — | $10M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $73M | -$49M | 0.0% | -54.9% | -326.9% | -7.0% | — | — | $336M |
| Mar '26 | $65M | -$43M | 0.0% | -52.7% | -102.5% | -9.0% | — | — | $131M |
| Dec '25 | $69M | -$68M | 0.0% | -91.0% | -105.2% | -12.8% | — | — | $135M |
| Sep '25 | $46M | -$61M | 0.0% | -125.2% | -52.6% | -11.0% | — | — | $117M |
| Jun '25 | $38M | -$72M | 0.0% | -182.7% | -45.6% | -12.1% | — | — | $109M |
| Mar '25 | $20M | -$85M | 0.0% | -417.9% | -39.5% | -13.2% | — | — | $154M |
| Dec '24 | $8M | -$94M | 0.0% | -1254.8% | -32.7% | -13.0% | — | — | $154M |
| Sep '24 | $13M | -$84M | 0.0% | -716.6% | -23.0% | -19.8% | — | — | $133M |
| Jun '24 | $4M | -$68M | 0.0% | -2120.5% | -15.7% | -14.3% | — | — | $105M |
| Mar '24 | $0 | -$72M | — | — | -14.7% | -13.3% | — | — | $115M |
| Dec '23 | $0 | -$72M | — | — | -13.1% | -11.8% | — | — | $295M |
| Sep '23 | $0 | -$51M | — | — | -14.2% | -12.8% | — | — | $95M |
| Jun '23 | $0 | -$45M | — | — | -11.2% | -10.3% | — | — | $97M |
| Mar '23 | — | -$41M | — | — | -9.4% | -8.9% | — | — | $58M |
| Dec '22 | — | -$39M | — | — | -8.4% | -7.9% | — | — | $74M |
| Sep '22 | — | -$35M | — | — | -10.5% | -9.8% | — | — | $71M |
| Jun '22 | — | -$38M | — | — | -10.4% | -9.2% | — | — | $120M |
| Mar '22 | — | -$37M | — | — | -9.9% | -8.8% | — | — | $189M |
| Dec '21 | $127M | $96M | 0.0% | 75.6% | 23.6% | 21.4% | — | — | $222M |
| Sep '21 | $12M | -$21M | 0.0% | -161.9% | -10.4% | -8.6% | — | — | $71M |
How the market has priced SNDX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Syndax Pharmaceuticals Inc's revenue has grown 157.7% per year. These are computed facts, not advice.
As of FY2025, Syndax Pharmaceuticals Inc reported — of total debt against $135M of cash; operating income covered interest expense -45514.0×.
In FY2025, gross margin was —, operating margin -158.4%, and net margin -165.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.